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Abstract
Background:  Peripheral  arterial  disease  (PAD),  a  major  manifestation  of  atherosclerosis,  is
associated with significant cardiovascular morbidity, limb loss and death. However, mechanisms
underlying the genesis and progression of the disease are far from clear. Genome-wide gene
expression  profiling  of  clinical  samples  may  represent  an  effective  approach  to  gain  relevant
information.
Results:  After  histological  classification,  a  total  of  30  femoral  artery  samples,  including  11
intermediate lesions, 14 advanced lesions and 5 normal femoral arteries, were profiled using
Affymetrix microarray platform. Following real-time RT-PCR validation, different algorithms of
gene selection and clustering were applied to identify differentially expressed genes. Under a
stringent cutoff, i.e., a false discovery rate (FDR) <0.5%, we found 366 genes were differentially
regulated in intermediate lesions and 447 in advanced lesions. Of these, 116 genes were overlapped
between  intermediate  and  advanced  lesions,  including  68  up-regulated  genes  and  48  down-
regulated  ones.  In  these  differentially  regulated  genes,  immune/inflammatory  genes  were
significantly up-regulated in different stages of PAD, (85/230 in intermediate lesions, 37/172 in
advanced lesions). Through literature mining and pathway analysis using different databases such as
Gene Ontology (GO), and the Kyoto Encyclopedia of Gene and Genomics (KEGG), genes involved
in immune/inflammatory responses were significantly enriched in up-regulated genes at different
stages  of  PAD(p  <  0.05),  revealing  a  significant  correlation  between  immune/inflammatory
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responses and disease progression. Moreover, immune-related pathways such as Toll-like receptor
signaling and natural killer cell mediated cytotoxicity were particularly enriched in intermediate and
advanced lesions (P < 0.05), highlighting their pathogenic significance during disease progression.
Conclusion: Lines of evidence revealed in this study not only support previous hypotheses,
primarily based on studies of animal models and other types of arterial disease, that inflammatory
responses may influence the development of PAD, but also permit the recognition of a wide
spectrum of immune/inflammatory genes that can serve as signatures for disease progression in
PAD. Further studies of these signature molecules may eventually allow us to develop more
sophisticated protocols for pharmaceutical interventions.
Background
Peripheral  arterial  occlusive  disease  (PAD)  is  a  major
manifestation of atherosclerosis and is commonly found
in elderly patients. Epidemiological studies have shown
that PAD affects 8 to 10 million adults in the United States
[1]. Most patients with PAD are asymptomatic. The dis-
ease is primarily diagnosed by an ankle brachial index
(ABI) < 0.9. The most common symptom of mild-to-mod-
erate PAD is intermittent claudication, which is present in
about one third of symptomatic patients [1]. In addition
to leg symptoms, patients with PAD are at an increased
risk for developing new coronary events and eventually
death  from  cardiovascular  disease.  Although  conven-
tional  procedures  such  as  stents,  arterectomies,  angi-
oplasty,  and  bypass  surgery  have  been  successful  in
improving clinical symptoms of PAD to a large extent [2],
ultimately elimination of the disease may require sophis-
ticated protocols of pharmaceutical interventions, which
may depend on better understanding of molecular mech-
anisms involved in the disease.
Previous studies have implicated the involvement of the
immune system in atherosclerosis formation and progres-
sion. Animal models have been used to test the contribu-
tions of components of the immune system [3,4]. Cellular
involvement of macrophages was found to be important
in the formation and progression of atherosclerosis in ani-
mal  models  [4].  In  addition,  various  immune-related
genes have been examined in an atherosclerosis animal
model, and genes such as CXCR6, CXCL10, CXCR3 and
CXCL16/scavenger  receptor  have  been  shown  to  be
involved in the progression of atherosclerosis in animal
models [5-8]. In humans, many immune cells such as
macrophages,  lymphocytes,  mast  cells,  and  T  cells  are
found in atherosclerosis [9]. These findings suggest that
the immune system plays important roles in atherogene-
sis. However, data available to date are primarily derived
from studies of atherosclerosis in the coronary or/and the
carotid arteries, whereas data derived from clinical sam-
ples of PAD appear to be particularly limited.
In  the  past  decade,  microarray  analysis  using  high-
throughput  screening  technology  has  emerged  as  an
important tool to study gene expression patterns and to
study molecular events in complex diseases [10-12]. In
this study, Affymetrix GeneChips were used to perform
gene  expression  profiling  of  femoral  atherosclerotic
lesions to fully characterize the peripheral arterial wall
gene expression patterns associated with atherosclerosis.
By  statistical  analysis,  hundreds  of  known  and  novel
genes were identified that differentially express in PAD.
Genes  involved  in  immune/inflammatory  responses
appeared to be significantly enriched in the set of genes
up-regulated in different stages of PAD. To further exam-
ine the expression patterns of individual genes in the con-
text of particular biological or molecular pathways, gene
functional enrichment was performed using Gene Ontol-
ogy  and  KEGG  database.  The  results  revealed  that
immune system-related categories and pathways were sig-
nificantly overrepresented in the progression of the dis-
ease,  suggesting  that  up-regulation  of  immune/
inflammatory genes may be critical components of the
disease progression expression signature associated with
atherosclerosis. These findings may provide new insights
and foster a better understanding of the mechanism of
PAD.
Results
Patient classification and outcome
Histological  characterization  of  30  collected  peripheral
artery samples was conducted based on the criteria of the
American Heart Association. Of these samples, 15 were
classified as grade III (intermediate lesions), one as grade
IV and fourteen as grade V (advanced lesions). Among
them, 11 intermediate lesions samples (grade III) and 14
advanced lesions samples (grade V) had RNA of sufficient
quality  and  quantity  for  hybridization.  Representative
images of the different stages are shown in Figure 1. Fur-
ther details of these 25 samples are listed in Table 1. As
shown, there was no significant difference between the
intermediate  lesions  and  the  advanced  lesions  group
except for indications of hypertension. In the intermedi-
ate  lesions  group,  4  patients  (36.4%)  presented  with
hypertension, while 9 hypertensive patients (64.3%) were
found in the advanced lesions group.BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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Differentially regulated genes in intermediate lesions
Identifying differential expression genes was achieved for
different stages by using Significance Analysis of Microar-
rays (SAM) with a false discovery rate (FDR) of 0.5%.
Comparative analysis revealed that 366 genes were differ-
entially expressed in intermediate lesions when compared
to normal femoral arteries, of which 230 genes were up-
regulated and 136 were down-regulated [see Additional
file  1].  The  100  most  differentially  expressed  genes
between intermediate lesions and normal femoral arteries
are  shown  in  Figure  2A.  Notably,  in  the  up-regulated
genes, up to 85 genes have been reported to be involved
in  immune  response,  such  as  HLA-DQB1,  HLA-DRB1,
CCR1, CXCR4, C1QB and TLR7 [see Additional file 2]. In
addition, a large number of genes known to encode pro-
teins  crucial  for  proteolysis  (CTSB,  CTSC,  CTSD  and
CTSS) and cell proliferation (BTG1, BTG2, CDKN1A, and
MCM5) appeared to be significantly changed. Since BTG1
and BTG2 are known to be involved in anti-proliferation
activities, it can be of interest to further investigate their
potential roles in PAD in detail. MCM5 is heavily involved
in  chromosomal  stability.  Among  the  down-regulated
genes, those involved in calcium signaling (CAMK2G),
transport (SLC22A3, CYP1A1 and ATP5H), metabolism
(GCSH and PLA2G4A), and protein amino acid dephos-
phorylation  (PTPN20)  were  found  to  be  significantly
down-regulated. The Gene Ontology functional categories
in  which  intermediate  lesions  are  overrepresented  are
illustrated in Table 2 and additional data [see Additional
file 3]. As shown in the table, the most significant biolog-
ical  process  categories  in  the  up-regulated  genes  are
immune response, humoral immune  response, inflam-
matory response, and T cell proliferation (Z-score>5). For
down-regulated genes, the significant ones mainly repre-
sent metabolism and catabolism-related categories.
Differentially regulated genes in advanced lesions
When advanced lesions were compared to normal femo-
ral arteries, 447 genes were identified, of which 172 genes
were  up-regulated  and  275  were  down-regulated  [see
Additional file 4]. The list of the 100 most differentially
expressed genes is shown in Figure 2B. Interestingly, up to
37 genes involved in the immune system response, such
as CCR1, CX3CR1, TLR1 and TLR7, were found to be up-
Table 1: Patient characteristics for the 25 samples in the microarray analysis
Intermediate lesions group (n = 11) Advanced lesions group (n = 14)
Age* 76.1 ± 4.68 76.6 ± 3.79
Male, n (%) 8(72.7) 12(85.7)
Hypertension†, n (%)
Yes 4(36.4) 9(64.3)
no 7(63.6) 5(35.7)
Hypercholesterolemia, n (%)
Yes 9(81.8) 11(78.6)
no 2(18.2) 3(21.4)
Diabetes, n (%)
Yes 7(63.6) 10(71.4)
no 4(36.4) 4(28.6)
*as mean ± SD.
† P < 0.05 (Student t test)
Histological characteristics of various severities of femoral  atherosclerotic lesions in PAD patients Figure 1
Histological characteristics of various severities of 
femoral atherosclerotic lesions in PAD patients. HE 
stain analysis of histological characteristics of collected femo-
ral non-atherosclerotic arteries and atherosclerotic arteries. 
8 um cryostat sections were stained with hematoxylin and 
eosin, dehydrated in graded alcohol, and cover-slipped with 
permanent mounting solution after xylene clearing. Three 
representative samples are listed: normal artery (A, B, C), 
intermediate lesions (D, E, F), and advanced lesions (G, H, I).BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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regulated in advanced lesion [see Additional file 5], which
might suggest that these immune/inflammatory related
genes could serve as expression signatures characterizing
different stages of PAD. In addition, genes constituting a
major portion of the vascular extracellular matrix were sig-
nificantly  up-regulated  in  advanced  lesions,  including
COL1A1, COL3A1, COL1A2, COL5A1, COL6A1, COL6A3
and LAMB1, suggesting that these genes could be involved
in the femoral artery occlusion in PAD. GO analysis fur-
ther confirmed the above findings, by highlighting catego-
ries  of  immune  response,  humoral  immune  response,
inflammatory response and I-kappaB kinase/NF-kappaB
cascades (Z-score>5) (Table 3 and Additional file 6). For
down-regulated  genes,  those  involved  in  ion  transport
(GRIA2  and  SLC22A3)  and  protein  folding  (DNAJB5)
appeared to be the most significantly down-regulated in
advanced lesions. GO analysis showed that the most sig-
nificant  categories  for  down-regulated  genes  were
response to protein stimulus, RNA metabolism, and pro-
tein folding (Table 3 and Additional file 6).
In parallel, further data analysis revealed that many genes
were over-represented in both intermediate and advanced
lesions vs. normal controls. Of these genes, 68 were found
to be commonly up-regulated and 48 were found to be
commonly down-regulated (Figure 3). The list of com-
Table 2: Biological process categories overrepresented in intermediate lesions
GO Name Z-score P-value
For up-regulated genes 
immune response 14.491 0.000
antigen processing, endogenous antigen via MHC class I 3.821 0.014
antigen processing, exogenous antigen via MHC class II 5.968 0.001
cellular defense response 5.669 0.000
cell-mediated immune response 3.093 0.038
T-helper 1 type immune response 3.214 0.035
humoral immune response 9.451 0.000
complement activation 3.608 0.016
inflammatory response 8.515 0.000
neutrophil chemotaxis 6.629 0.004
leukocyte adhesion 4.767 0.013
immune cell activation 3.268 0.011
immune cell migration 6.25 0.000
cell surface receptor linked signal transduction 2.082 0.042
integrin-mediated signaling pathway 2.633 0.035
intracellular signaling cascade 4.367 0.000
MAPKKK cascade 2.413 0.037
myeloid cell differentiation 2.876 0.042
lipid transport 3.255 0.011
Phagocytosis 4.757 0.005
Apoptosis 2.091 0.049
cell proliferation 4.257 0.000
T cell proliferation 5.489 0.003
oxygen transport 3.255 0.016
icosanoid metabolism 3.524 0.010
lipoprotein metabolism 3.291 0.017
For down-regulated genes
cellular catabolism 2.708 0.014
amine catabolism 3.599 0.011
glycine catabolism 8.457 0.003
glycine metabolism 5.817 0.008
ubiquitin cycle 2.092 0.041
protein folding 3.088 0.008
Endocytosis 2.521 0.032
GO analysis was applied to differentially expressed genes in intermediate lesions compared with normal controls. Similar significant categories were 
not included to reduce redundancy. The first half of the table indicates categories highly significant for up-regulated genes; the second half of the 
table shows categories highly significant for down-regulated genes. Calculated p-values and Z-scores for each category are shown. The 
corresponding cell component categories and molecular function categories are available in additional data [see Additional file 3]BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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Heatmap of the 100 most differentially expressed genes in intermediate lesions and advanced lesions, respectively Figure 2
Heatmap of the 100 most differentially expressed genes in intermediate lesions and advanced lesions, respec-
tively. SAM analysis reveals genes with differential expression in PAD. This analysis compared plaques from within arteries of 
either intermediate (n = 11) or advanced lesions (n = 14) to normal control group, respectively. Heatmap representation of 
the 100 most differentially expressed in intermediate lesions (A) and advanced lesions (B). Samples are displayed in columns 
and genes in rows. Gene expression is represented as a color, normalized across each row, with brighter red for higher values 
and brighter green for lower values. Gene symbols are listed to the right. N (Normal control group), Int (intermediate lesions 
group), Ad(advanced lesions group). The list of differentially expressed genes in intermediate lesions and advanced lesions is 
provided [see Additional file 1 and Additional file 4].BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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monly up-regulated genes is available [see Additional file
7]. Some of these overlapping genes, such as CTSB, CCR1,
ALOX5, and SPP1, have been previously reported to play
important  roles  in  atherogenesis  [13-16].  Accordingly,
these commonly regulated genes can therefore be impor-
tant for the progression of PAD. In contrast, a much larger
number of genes appear to be characteristically expressed
in either intermediate lesions or advanced lesions, which
may therefore serve as stage-specific signatures of PAD.
Differential gene expression in disease progression
Intermediate lesions and advanced lesions represent dif-
ferent stages in disease progression of PAD. Identification
of genes that exhibit characteristic expression patterns in
different stages may provide information relevant to the
progression of PAD. For this reason, expression profiles of
normal  arteries,  intermediate  lesions  and  advanced
lesions were analyzed by the SAM multiclass method. Out
of this analysis, 614 genes appeared to be differentially
expressed in the progression of PAD with a FDR<0.5%
[see  Additional  file  8].  Hierarchical  clustering  analysis
suggested that the expression patterns of the genes could
be assigned to three major groups (Figure 4). The first
group  represents  those  genes  commonly  expressed  in
both intermediate and advanced lesions (Cluster II). GO
terms indicate that these genes are mainly involved in the
immune  response,  inflammatory  response,  cellular
defense  and  various  signaling  pathways  (Table  4  and
Additional file 9). These results further support the notion
that the immune system may play an important role in the
progression of PAD. The second group represents specifi-
cally down-regulated genes in advanced lesions (Cluster
II).  GO  terms  indicate  that  these  genes  are  primarily
involved in cell cycle, apoptosis, multicellular organism
development and protein folding (Table 4 and Additional
file 9). Genes in the third group are represented by those
down-regulated  in  both  intermediate  lesions  and
advanced  lesions  (Cluster  III).  GO  terms  indicate  that
these genes are mainly involved in neurogenesis, protein
modification, RNA splicing, and blood pressure regula-
tion (Table 4 and see Additional file 9). In addition, we
have performed data analysis restricted to male subjects.
Up to 85% genes identified in male subjects are the same
as those identified in the total samples (data not shown),
which suggests that the potential gender-biases is mini-
mal.  Taken  together,  genes  commonly  up-regulated  in
intermediate  and  advanced  stages  are  typically  repre-
sented by those involved in immune and inflammatory
responses, implicating enhanced immune response activ-
ities during the progression of the disease, whereas down-
regulated genes in the both disease stages are primarily
represented by those involved in various aspects of cell
proliferation and differentiation.
Validation of gene transcription by real-time PCR
Real-time PCR is still the gold standard for quantitative
analysis  of  mRNA.  In  order  to  validate  the  microarray
results, RT- PCR was carried out on the same set of sam-
ples that were analyzed by the microarray approach. The
results were highly correlated with those from the array
data. (The correlation coefficient for microarray and RT-
PCR was 0.835 ± 0.076). Representative RT-PCR results of
6 genes are shown in Figure 5.
Table 3: Biological process categories overrepresented in 
advanced lesions
GO Name Z-score P-value
For up-regulated genes 
immune response 6.305 0.000
cellular defense response 2.94 0.026
humoral immune response 5.392 0.000
inflammatory response 6.179 0.000
immune cell migration 4.778 0.014
intracellular signaling cascade 4.297 0.001
small GTPase mediated signal transduction 2.372 0.024
I-kappaB kinase/NF-kappaB cascade 6.408 0.000
T cell proliferation 4.186 0.016
induction of apoptosis 3.709 0.007
oxygen transport 4.778 0.003
amine transport 3.051 0.024
anion transport 3.373 0.006
phosphate transport 6.139 0.000
organic acid transport 2.634 0.039
nucleoside monophosphate metabolism 5.853 0.001
cell adhesion 3.958 0.000
For down-regulated genes
response to protein stimulus 6.79 0.000
response to unfolded protein 6.79 0.000
integrin-mediated signaling pathway 4.36 0.003
Apoptosis 2.838 0.003
muscle cell differentiation 3.771 0.032
vasculature development 3.795 0.005
neuron differentiation 3.993 0.003
vitamin transport 3.771 0.023
RNA metabolism 3.476 0.000
RNA splicing 3.497 0.005
glutamine metabolism 4.901 0.004
macromolecule metabolism 2.214 0.023
protein folding 5.643 0.000
cell-matrix adhesion 2.605 0.036
peptide hormone secretion 5.401 0.004
GO analysis was applied to differentially expressed genes in advanced 
lesions compared with normal controls. Some other selected 
categories are shown. The first half of the table indicates categories 
highly significant for up-regulated genes; the second half of the table 
shows categories highly significant for down-regulated genes. 
Calculated p-values and Z-scores for each category are shown. The 
corresponding cell component categories and molecular function 
categories are available in additional data [see Additional file 6]BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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Over-represented genes in both intermediate lesions and advanced lesions Figure 3
Over-represented genes in both intermediate lesions and advanced lesions. A. The genes whose expressions were 
significantly changed in intermediate lesions and advanced lesions, respectively, are shown in a Venn diagram. B, C. Heatmap 
representation of commonly up-regulated genes (B) and commonly down-regulated genes (C) in overlapping genes, respec-
tively. Samples are displayed in columns and genes in rows. Gene expression is represented as a color, normalized across each 
row, with brighter red for higher values and brighter green for lower values. Gene symbols are listed to the right. N (Normal 
control group), Int (intermediate lesions group), Ad (advanced lesions group).BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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Transcription factors enrichment analysis
Transcription factors appear to play important roles in the
development or progression of atherosclerosis [17,18]. To
address whether specific transcription factors are involved
in the regulation of genes associated with the progression
of PAD, we conducted a transcription factor binding site
enrichment  study  by  analyzing  cross-species  conserved
binding sites in promoter regions of genes differentially
regulated during progression of PAD. Through the Fisher
Exact test, binding sites of transcription factor AP-1 and
CREB  appeared  to  be  significantly  enriched  (q-value  <
0.05). AP-1 is a transcription factor known to be involved
in  various  cellular  processes.  In  atherosclerosis,  it  has
been reported in gene regulation of microphages, vascular
smooth muscle cells and epithelial cells [19,20]. In dis-
ease progression, AP-1 was enriched to regulate expres-
sion of 72 genes (Figure 6A and Additional file 10). The
enrichment of AP1 binding sites in regulated genes associ-
Table 4: GO discovered categories for disease progression manner analysis
GO Name Z-Score P-value
For Cluster I
immune response 8.908 0.000
inflammatory response 7.643 0.000
cellular defense response 5.938 0.001
chemotaxis 7.611 0.000
cell surface receptor linked signal transduction 2.937 0.009
cytokine and chemokine mediated signaling pathway 4.378 0.004
JAK-STAT cascade 3.254 0.020
MAPKKK cascade 3.062 0.006
endocytosis 1.956 0.049
angiogenesis 4.452 0.000
cell adhesion 4.580 0.000
ion homeostasis 3.090 0.010
For Cluster II
apoptosis 3.871 0.002
cell cycle 4.108 0.000
cell growth 2.285 0.037
epidermal cell differentiation 3.075 0.044
protein folding 3.677 0.001
macromolecule metabolic process 3.022 0.005
RNA metabolic process 5.378 0.000
transcription 4.593 0.000
peripheral nervous system development 2.950 0.046
multicellular organismal development 3.927 0.000
vitamin transport 4.426 0.008
response to stimulus 4.579 0.000
circadian rhythm 5.090 0.001
For Cluster III
neurogenesis 2.612 0.014
neuron recognition 3.315 0.046
cell motility 2.093 0.042
glycogen metabolic process 2.999 0.025
protein modification process 3.166 0.001
RNA processing 2.183 0.042
RNA splicing 2.591 0.021
phosphate metabolic process 2.346 0.024
blood pressure regulation 4.028 0.008
heart contraction 2.901 0.022
GO analysis was applied to differentially expressed genes in each cluster group. Some selected categories are shown. The Calculated p-values and 
Z-scores for each category are shown. The detailed GO results are provided in the additional data [see Additional file 9].BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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Hierarchical clustering analysis of the differentially expressed genes in disease progression Figure 4
Hierarchical clustering analysis of the differentially expressed genes in disease progression. The differentially 
expressed genes analyzed by hierarchical clustering method in disease progression. The genes were classified into three major 
clusters by visual inspection. Clustering method: Average linking; Similarity measure: Euclidean distance. Samples are displayed 
in columns and genes in rows. Gene expression is represented as a color, normalized across each row, with brighter red for 
higher values and brighter green for lower values. N (Normal control group), Int (intermediate lesions group), Ad (advanced 
lesions group). The list of differentially expressed genes in disease progression is provided [see Additional file 8].BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
Page 10 of 18
(page number not for citation purposes)
Enriched transcription factors and their putative target genes in disease progression Figure 6
Enriched transcription factors and their putative target genes in disease progression. Putative targets of transcrip-
tion factors were curated based on results by Xiaohui Xie. Fisher Exact test showed that two transcription factors (AP-1 and 
CREB) were significantly enriched in disease progression (q-value <0.05). AP-1 and CREB were enriched to regulate 72 and 55 
genes expression, respectively. A, B. The top 20 putative target genes of AP-1 and CREB were listed, respectively. A list of the 
enriched transcription factor and their putative targets is provided [see Additional file 10 and Additional file 11].
Real-time PCR and the relative expression level of six genes Figure 5
Real-time PCR and the relative expression level of six genes. Six genes mRNA in normal femoral artery (N, black 
round), intermediate lesions (Int, ascending triangle) and advanced lesions (Ad, descending triangle) were determined by real-
time PCR and presented as a ratio to GAPDH mRNA. mRNA abundance in intermediate lesions or advanced lesions was dif-
ferentially expressed (*P < 0.05, and **P < 0.01, respectively) when normal samples were used for comparison.BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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ated  with  PAD  progression  may  therefore  suggest  an
important role played by this transcription factor in the
development of PAD. Through literature mining, indeed,
some of the potential targets of AP1 appear to be previ-
ously reported as target genes of AP-1 [21-24]. CREB is a
member of the leucine zipper family of DNA binding pro-
teins. This transcription factor binds as a homodimer to
the cAMP-responsive element and induces transcription
of genes in response to hormonal stimulation [25]. A total
of 55 genes were recognized as potential targets of CREB
(Figure 6B and Additional file 11). Although further stud-
ies are need to elucidate detailed roles played by AP1 and
CREB in PAD progression, significantly enriched binding
sites and highly correlated with signature genes of PAD
progression suggest that these two transcription factors
may play critical roles in the development of PAD.
Pathways identification by overabundant genes
A pathway analysis database, KEGG, was then applied to
genes  differentially  regulated  in  intermediate  and
advanced lesions. Several overrepresented pathways were
identified, and the enriched pathways appeared not to be
independent of one another, many genes involved in one
pathway could be also involved in another pathway. This
interaction is illustrated in Figure 7, and pathway abbrevi-
ations can be found in Table 5. As demonstrated, many
immune-related pathways were significantly over-repre-
sented in intermediate and/or advanced lesions including
TLR, NK, BCR, FER, APP, CCC and LTEM pathways. These
findings, on the one hand, provide evidence supporting
previous  hypotheses  that  immune/inflammatory
responses  play  important  roles  in  the  development  of
PAD, and on the other hand, demonstrate that particular
components  of  immune/inflammatory  systems  can  be
crucial  for  the  genesis  and  progression  of  PAD.  For
instance, TLR and NK pathways are shown to be particu-
larly  overrepresented  in  both  intermediate  lesions  and
advanced  lesions,  highlighting  their  functional  impor-
tance in the disease. The TLR pathway is shown in Figure
8 with the differentially regulated genes indicated.
Protein validation of TLR7 expression
Members of the Toll receptor family are key mediators of
innate immunity. They respond to various pathogen-asso-
ciated stimuli and transduce complex signaling responses
that are required for inflammation and for the subsequent
development of adaptive immunity [26]. In atherosclero-
sis, TLR-mediated signaling cascades are observed in mac-
rophages, mast cells and endothelial cells [27,28]. Data
shown in this setting demonstrate that genes involved in
TLR-mediated pathway are significantly up-regulated in
intermediate or advanced lesions, including TLR1, TLR2,
TLR7, and MyD88. TLR1 and TLR2 have been previously
reported to be significantly regulated in atherosclerosis
and their functional roles have been widely investigated
in  atherosclerosis  [29,30].  However,  the  expression  of
TLR7  in  atherosclerosis  has  not  been  reported  before.
TLR7 mediates innate responses by recognizing oligonu-
Table 5: KEGG biological pathways for differentially expressed genes in different stages
KEGG Pathway Name Pathway ID Genes involved P-Value
For intermediate lesions
Type I Diabetes Mellitus(TIDM) Hsa04940 9 0.002
Antigen Processing and Presentation(APP) Hsa04612 13 0.003
Complement and Coagulation Cascades(CCC) Hsa04610 12 0.003
Cell Adhesion Molecules(CAM) Hsa04514 17 0.005
Toll-Like Receptor Signaling Pathway(TLR) Hsa04620 13 0.013
Natural Killer Cell Mediated Cytotoxicity(NK) Hsa04650 15 0.029
For advanced lesions
Focal Adhesion(FA) Hsa04510 25 0.000
ECM-Receptor Interaction(ECM) Hsa04512 15 0.000
Toll-Like Receptor Signaling Pathway(TLR) Hsa04620 13 0.002
Regulation of Actin Cytoskeleton(RAC) Hsa04810 20 0.005
Fc Epsilon RI Signaling Pathway(FER) Hsa04664 10 0.012
MAPK Signaling Pathway(MAPK) Hsa04010 22 0.019
Natural Killer Cell Mediated Cytotoxicity(NK) Hsa04650 13 0.021
Long-Term Potentiation(LTP) Hsa04720 8 0.030
Cell Communication(CC) Hsa01430 12 0.032
B Cell Receptor Signaling Pathway(BCR) Hsa04662 8 0.042
Genes identified from SAM under FDR<1% were tested for overrepresentation within the pathways for the KEGG under the modified Fisher Exact 
test assumption; p-Value and genes involved in the pathway are provided for each pathwayBMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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Interactions of KEGG pathways for differentially expressed genes in different stages of PAD Figure 7
Interactions of KEGG pathways for differentially expressed genes in different stages of PAD. Pathways are 
enriched in intermediate lesions (A) and advanced lesions (B), respectively. Many genes involved in one pathway could also be 
involved in another pathway. A, B. Networking displayed the interaction of pathways in intermediate lesions and advanced 
lesions, respectively.
Over-representation of Toll-like receptor signaling pathway genes Figure 8
Over-representation of Toll-like receptor signaling pathway genes. Analysis of over-representation of differentially 
expressed genes in pathway from KEGG. The Toll-like receptor signaling pathway is illustrated with significantly regulated 
genes highlighted.BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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cleotide  based  (RNA-)  molecular  patterns  in  endocytic
compartments. Our data show that it is significantly up-
regulated  in  both  intermediate  and  advanced  lesions.
Western-blot analysis was performed to further validate its
expression on the protein level (Figure 9). The function of
TLR7 in atherogenesis is currently under further investiga-
tion.
Discussion
In the present study, we first examined the gene expres-
sion profiles of PAD. Data analysis identified a number of
genes that might be significantly correlated with different
levels of PAD severity. The list of differentially expressed
genes  in  intermediate  and  advanced  lesions  contains
many genes which can be important for atherosclerosis.
Most of these genes have not been reported to be related
to atherosclerosis before. For example, MAP4K4 is a mem-
ber of the serine/threonine protein kinase family. It has
been  shown  to  specifically  activate  MAPK8/JNK  and
mediate the TNF-alpha signaling pathway [31,32]. In this
study, it was significantly and consistently up-regulated in
both intermediate and advanced lesions.
A large multidisciplinary study is currently underway to
comprehensively assess PAD at multiple levels [33], The
goal  of  that  study  is  to  investigate  300  symptomatic
patients with PAD undergoing medical management with
or without vascular intervention by lower extremity angi-
oplasty/stenting  or  vein  graft  bypass,  and  to  test  the
hypothesis that the systemic inflammatory response after
vascular intervention influences the local milieu responsi-
ble for vascular repair and adaptation [33]. Identification
of genes through the work may be significant in the selec-
tion of candidate genes that can be investigated through
these  cases-control  genetic  epidemiology  studies.  Our
research supports the idea that immune responses play a
key role in the development of PAD.
In this report, immune related genes were shown to be sig-
nificantly  expressed  during  the  development  of  PAD.
Gene functional analysis further revealed that immune
related categories and pathways were significant enriched
in the different stages of PAD. In these immune related
genes, several genes have been shown to modulate the
development of atherosclerosis in mice models. For exam-
ple, IgG Fc receptors (FcgammaRs) play a role in activating
the immune system and in maintaining peripheral toler-
ance. Previous research suggested that Fc  receptor defi-
ciency protects against atherosclerosis in Apolipoprotein-
E  knockout  mice  [34].  The  results  suggest  that  broad-
range inhibitors of immune and inflammatory responses
can be considered as potential targets for the treatment of
PAD.  However,  gene  expression  patterns  of  immune
related genes can be different in different stages of PAD.
For example, in intermediate lesions, MHC class II mole-
cules  were  significantly  up-regulated  including  HLA-
DMA,  HLA-DMB,  HLA-DPB1,  HLA-DQB1,  HLA-DRA,
HLA-DRB1 and HLA-DRB5. MHC class II molecules are
normally restricted to a subset of antigen presenting den-
dritic cells, B cells, macrophages, and thymic epithelium
cells [35]. These cells can be detected close to CD4+ T cells
and present peptides to the T cells. The results suggest that
there can be an ongoing immune activation in the inter-
mediate lesions. However, MHC class II molecules were
not differentially expressed in advanced lesions, even with
a higher false discovery rate, which may suggest that the
HLA-mediated immune activation may occur mainly in
the progression stages of PAD. In addition, complement
molecules were also significantly up-regulated in interme-
diate lesions, not in advanced lesions. Previous studies
have implicated that activation of the complement system
is probably associated with the initiation and progression
of atherosclerosis [36,37]. Our data thus provide direct
evidence from clinical samples demonstrating that com-
plement system mainly play a role in the development
stages of PAD. It is therefore conceivable that different and
complex immune/inflammatory responses may take place
at different stages of PAD.
Atherosclerosis is a systemic, multifocal disease leading to
various symptoms and clinical events including cardio-
vascular disease, cerebrovascular disease, and peripheral
arterial disease. Our results reveal that many genes identi-
fied in the report are also expressed in coronary or carotid
atherosclerotic lesions. For example, C3AR1 and C5R1 are
receptors of C3 (C3a) and C5a respectively. A recent study
shows  that  C3AR1  and  C5R1  are  expressed  in  human
Significant expression of TLR7 in femoral atherosclerotic  lesions Figure 9
Significant expression of TLR7 in femoral atheroscle-
rotic lesions. Western blot analysis of TLR7 in atheroscle-
rotic femoral arteries (As, n = 3) and normal femoral arteries 
(N, n = 3). The protein level of Cathepsin S, whose expres-
sion was previously validated in atherosclerosis, was also 
examined in femoral atherosclerotic lesions. Beta – actin 
served as a loading control.BMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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atherosclerotic  coronary  plaques  [38].  Double  immun-
ofluorescence staining has shown that the plaque of cells
that  express  both  C3aR  and  C5aR  are  macrophages,  T
cells, endothelial cells, and sub-endothelial smooth mus-
cle cells. In addition, gene expression changes between
atherosclerosis from coronary and carotid artery samples
have been measured by microarray technology in recent
years. One study using microarray found that 82 genes
were differentially expressed in both animal model and
human coronary artery atherosclerosis disease [39]. Our
data confirmed 29 genes and 18 genes had significantly
different expression in intermediate lesions and advanced
lesions, respectively. Moreover, these genes had expres-
sion trends similar to the ones found in our data, but our
data showed higher fold-changes. In these overlapping
genes,  14  were  reported  to  be  involved  in  immune
response. Another microarray study found that 206 genes
were differentially expressed in aortic atherosclerosis sam-
ples [40]. Our data confirms 43 genes and 32 genes had
significantly  different  expression  in  intermediate  and
advanced lesions (FDR<1%), respectively. Importantly, in
these overlapping genes, 15 were reported to be involved
in immune response. Taken together, the results suggested
that immune response is a common feature in atheroscle-
rosis-related diseases. Our microarray study differs from
prior microarray studies in the array type, sample type,
sample classification, and analytical techniques. Never-
theless, the high level of overlapping genes suggests that
there are similar molecular mechanisms in the develop-
ment of peripheral arterial disease and other atherosclero-
sis-related diseases.
Several limitations of our approach should be noted. First,
hybridization-based microarrays, despite their immense
potential, have inherent shortcomings related to deficient
standardization of methods employed in normalization,
statistical analysis, and so on [41,42]. In this study, we
have attempted to limit these shortcomings by selecting
subjects who were phenotypically similar to each other
except for hypertension. In addition, the initial phases of
data analysis, we used different normalization and statis-
tical methods to identify differentially expressed genes.
After choosing SAM, we used a rigorous false discovery
rate to minimize false positive results. Expression patterns
were validated by confirming mRNA expression patterns
with conventional molecular techniques. We attempted,
based on current literature, to suggest a potential func-
tional  role  for  genes  whose  expression  was  markedly
altered. Second, atherosclerosis is a slow, progressive dis-
ease that may start in childhood; entirely normal arteries
can only be obtained from young donors, a factor that can
affect gene expression measurements. Although previous
research and our data analysis suggest that age had very lit-
tle effect on genes, further work is needed to identify age-
related  genes.  Third,  the  relatively  small  number  of
patients did not allow us to assess serial changes in the
disease development in more detail as would have been
possible in animal models [36]. Furthermore, we do not
know to what extent the observed changes in gene expres-
sion translate into protein synthesis and function, and
which  genes  cause  atherosclerosis.  Future  studies  are
needed to address these issues.
Conclusion
We first examined the gene expression profiles of PAD; the
results from this analysis provide an initial step towards a
better understanding of molecular mechanisms underly-
ing  PAD  development.  Differences  in  immune-related
responses were observable at the gene expression level.
These findings may be significant for understanding the
molecular basis of PAD and investigating pharmacologi-
cal approaches for the prevention and amelioration of
atherosclerosis in PAD.
Methods
Tissue Harvest
After obtaining informed consent, primary femoral artery
specimens containing atherosclerotic lesions were taken
from  30  patients  undergoing  surgical  bypass  or  limb
amputation  at  Shanghai  Ninth  People's  Hospital.  The
specimens were immediately rinsed once with PBS and
cut longitudinally by the surgeon. Three quarters of the
samples were stored at once in – 80°C for subsequent
total RNA extraction. The remaining samples were embed-
ded in OCT medium and snap frozen for further morpho-
logical  analysis.  Clinical  patient  parameters  were  also
registered. For controls, five normal femoral arteries were
obtained from healthy donors during organ transplanta-
tion (male, mean 31.6 years; range 22–45 years). These
five samples were without clinical or gross macroscopic
signs of atherosclerotic disease. The Local Ethical Com-
mittee approved all procedures in this investigation, and
proper  protocol  was  followed  throughout  the  entire
course of the experiment.
Histology
For each sample, cryostat sections of 8 um were stained
with hematoxylin for 10 min and eosin for 2 min, dehy-
drated in graded alcohol, and cover-slipped with perma-
nent mounting solution after xylene clearing.
RNA Isolation and Quantification
Total RNA was isolated from the samples using a Trizol
reagent (Invitrogen, Carlsbad, CA) and cleaned up using
RNeasy Micro Kit (Qiagen, Valencia, CA) techniques. In
brief, for each tissue, at least 100 mg sample was pulver-
ized under liquid nitrogen. After complete disruption of
the tissues, the Trizol reagent was added in the amount of
1 ml/100 mg. Total RNA was extracted using the protocol
supplied with the Trizol reagent. After isolation, the RNABMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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was cleaned up using the RNeasy Micro Kit. To remove
any  contaminating  genomic  DNA,  a  DNase  step  was
included, following the manufacturer's protocol. The RNA
quantity and quality were determined by an Agilent Bio-
analyzer  2100  and  an  Eppendorf  Biophotometer.  Any
RNA samples that showed degradation was excluded from
the study.
Microarray Experiment
One  microgram  of  total  RNA  was  used  for  generating
biotin labeled cRNA. The labeling reaction was performed
according to the standard Affymetrix® protocol to generate
a biotin-labeled cRNA probe. The samples were hybrid-
ized to the Affymetrix® Human Genome -U133A Gene-
chip,  stained,  washed  and  scanned  according  to  the
standard Affymetrix® protocol. The computer data files to
be used in data analysis (*.dat, *.cel, *.chp) were gener-
ated with the Affymetrix GeneChip Operating Software
(GCOS)  Version  1.4  (Affymetrix®),  using  the  statistical
algorithm provided. All chip samples were scanned using
the  same  instrument  and  followed  the  same  protocol.
Data quality assessment was then performed following
the  guidance  in  Affymetrix  data  analysis  fundamentals
manual. All quality control results met Affymetrix recom-
mended criteria.
Data process and analysis
The probe level intensity data were transferred to ArrayAs-
sist® Software (StrataGene; La Jolla, CA) for further analy-
sis.  For  comparison  of  differential  gene  expression
between  different  stage  groups,  the  background  was
removed and data were normalized in accordance to the
GC-RMA method [43]. GC-RMA takes into account the
GC content of the probe sequences when comparing the
expression intensities of the different probesets. Then, the
processed gene expression data were transformed into log
base 2 and filtered to delete the genes whose detection
calls were "absent" in all samples.
Microarray data analysis was carried out to identify indi-
vidual  genes  that  were  significantly  expressed  between
classes by the software package SAM (please see Availabil-
ity & requirements for more information), using   = 0.5.
Results from the difference analysis were clustered and
displayed using the Cluster3.0 and Treeview1.1.0 software
(please see Availability & requirements for more informa-
tion). Each list of differentially expressed genes was ana-
lyzed in the context of Gene Ontology (GO) in order to
identify groups of genes with similar functions, or proc-
essed using MAPPFinder (Gene MicroArray Pathway Pro-
filer;  please  see  Availability  &  requirements  for  more
information). For each gene ontology term, the probabil-
ity values were computed based on a hypergeometric dis-
tribution  test  by  comparing  (a)  the  number  of  genes
annotated by the gene ontology term in a given list of dif-
ferentially expressed genes with (b) the expected number
of such genes. Z-score>0 and p-values < 0.05 were consid-
ered significant categories.
Similar methods were used to identify curated pathways
that were significantly over-represented in the data using
KEGG database by using DAVID (please see Availability &
requirements for more information). For each pathway,
the probability values were computed based on a modi-
fied Fisher exact test. EASE p-values < 0.05 were consid-
ered significant categories. The enriched pathways are not
entirely separate from one another. For example, many
genes involved in MAPK signaling pathway can also be
involved  in  other  pathways,  such  as  NK  pathway.  The
interconnectedness information was manually extracted
from the pathway. Because the nature and complexity of
these interactions varied from pathway to pathway, a sim-
ple line connecting two pathways was used to represent
their interaction. The interaction map was generated for
the  interaction  of  enriched  pathways  using  CytoScape
software.
Transcription  factor  enrichment  analysis  was  also  per-
formed. The putative targets of transcription factors from
TRANSFAC (v7.4) were discovered by Xie et al [44] and
downloaded from the supplementary web site (please see
Availability & requirements for more information). All
the RefSeq IDs were converted to Entrez Gene ID accord-
ing to the mapping table downloaded from NCBI web site
(please see Availability & requirements for more informa-
tion). Enrichment of transcription factor targets was per-
formed as described previously [45]. The interaction map
was generated for the interaction of enriched transcription
factors and their putative target genes using CytoScape
software
Real-time QPCR Analysis
One  microgram  of  total  RNA  was  reverse  transcripted
using random hexamers and superscript -II reverse tran-
scriptase  (Invitrogen,  Carlsbad,  CA).  QPCR  was  per-
formed by using ABI prism 7900 (ABI, Foster City, CA)
and SYBR Green Detection (Toyobo, Japan). Primers were
designed by using the Primer Express 2.0 software and ver-
ified by using a BLAST search. Sequences of the primers
are listed [see Additional file 12]. The experimental condi-
tions followed the manufacturer's protocol and the data
were analyzed with sequence Detection Software 2.0 (ABI,
Foster City, CA). Relative expression of mRNA was calcu-
lated with the comparative CT method. To standardize the
amount of input RNA, the GAPDH gene was included. For
each sample, the experiment was performed in triplicate.
Western Blotting
Proteins were extracted after RNA isolation according to
the Introvigen protocol (Invitrogen, Carlsbad, CA) andBMC Genomics 2008, 9:369 http://www.biomedcentral.com/1471-2164/9/369
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measured  using  a  Bio-Rad  DC  protein  assay  (Bio-Rad,
Richmond, CA, USA). Aliquots of protein (100  g of pro-
tein each) were resolved on a 10% SDS-PAGE gel and
transferred  to  a  polyvinylidene  difluoride  membrane
(Millipore, Medford, MA, USA). The membrane was incu-
bated with a primary antibody overnight at 4°C and then
with a secondary antibody conjugated with alkaline phos-
phatase (1 h at room temperature), which was detected by
a chemiluminescence method. The following polyclonal
primary antibodies were used: anti-human TLR7 (1:300,
IMGENEX,  San  Diego,  CA),  anti-human  CTSS  (1:400,
Abcam  Inc),  anti-human  beta-action  (1:10000,  Abcam
Inc).
Statistics
The statistical significance of real-time results was exam-
ined with the nonparametric Mann-Whitney test, using
GraphPad Prism 4. In the experiment, p values < 0.05 were
considered  significantly  different  between  the  lesions
group and the normal artery group.
Availability & requirements
SAM  software  package:  http://www-stat.stanford.edu/
~tibs/SAM/
Cluster3.0  and  Treeview1.1.0  software:  http://bon
sai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/
sofe.htm
MAPPFinder (Gene MicroArray Pathway Profiler): http://
www.genmapp.org
DAVID: http://david.abcc.ncifcrf.gov/
Xie  et  al  Supplementary  Information:  http://
www.broad.mit.edu/seq/HumanMotifs/
NCBI  web  site:  ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/
gene2refseq.gz
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in each cluster, the calculated p-values and Z-scores for each category are 
shown in the table.
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2164-9-369-S9.doc]
Additional File 10
Table 10. 72 putative AP-1 target genes in disease progression. Affymetrix 
Probe Set ID, Gene Title, Gene Symbol, GO Biological Process, GO 
Molecular Function, GO Cellular Component, Unigene, Entrez Gene, 
Ensembl, Chromosome Number, Socre(d), Contrast, and q-value(%) are 
listed.
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Additional File 11
Table 11. 55 putative CREB target genes in disease progression. Affyme-
trix Probe Set ID, Gene Title, Gene Symbol, GO Biological Process, GO 
Molecular Function, GO Cellular Component, Unigene, Entrez Gene, 
Ensembl, Chromosome Number, Socre(d), Contrast, and q-value(%) 
were listed.
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Additional File 12
Table 12. The primer sequences of selected genes for real-time PCR.
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